Cross-country migration linked to people who inject drugs challenges the long-term impact of national HCV elimination programmes
Vrancken, B. ; Cuypers, L. ; Pérez, A.B. ; Chueca, N. ; Anton-Basantas, J. ; de la Iglesia, A. ; Fuentes, J. (Universidad de Zaragoza) ; Pineda, J.A. ; Téllez, F. ; Bernal, E. ; Rincón, P. ; Von Wichman, M.A. ; Fuentes, A. ; Vera, F. ; Rivero-Juárez, A. ; Jiménez, M. ; Vandamme, A.M. ; García, F.
Resumen: To the Editor:
As of 2018, the majority of Western European countries – including Spain – have lifted restrictions to therapy based on disease severity in the context of HCV infections.1 Long overdue, most national elimination programmes now also include access to care for people who inject drugs (PWID), 2 who are at the core of ongoing HCV transmission.3 Macías et al.4 have recently shown in this Journal that high viral cure rates can be achieved in this group, hereby providing evidence that targeting PWID in treatment programmes is worthwhile. However, the extent to which such national efforts can reduce the HCV burden not only depends on the uptake into care and treatment success rates, it is also determined by the relative importance of within-country transmission and virus importation from elsewhere.
As the chronic nature of most HCV infections hampers reliably reconstructing contact networks from patient interviews, virus genetic data can be a valuable alternative source of information for elucidating the geographic history of virus lineages (e.g. [5], [6]). Using such data, we have recently shown that for the most prevalent subtype among PWID in Spain (40%, 7), HCV1a, infections often link to infections abroad – in recent years >50% link to Western European countries, mostly European Union (EU) member states – as opposed to other infections ...
Idioma: Inglés
DOI: 10.1016/j.jhep.2019.08.010
Año: 2019
Publicado en: JOURNAL OF HEPATOLOGY 71, 6 (2019), 1270-1272
ISSN: 0168-8278
Factor impacto JCR: 20.582 (2019)
Categ. JCR: GASTROENTEROLOGY & HEPATOLOGY rank: 2 / 88 = 0.023 (2019) - Q1 - T1
Factor impacto SCIMAGO: 6.817 - Hepatology (Q1)
Financiación: info:eu-repo/grantAgreement/ES/FEDER/RD16-0025-0040
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/PI15-00713
Tipo y forma: (PostPrint)
Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)
Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace. No puede utilizar el material para una finalidad comercial. Si remezcla, transforma o crea a partir del material, no puede difundir el material modificado.
Exportado de SIDERAL (2021-02-24-12:54:45)
Visitas y descargas
As of 2018, the majority of Western European countries – including Spain – have lifted restrictions to therapy based on disease severity in the context of HCV infections.1 Long overdue, most national elimination programmes now also include access to care for people who inject drugs (PWID), 2 who are at the core of ongoing HCV transmission.3 Macías et al.4 have recently shown in this Journal that high viral cure rates can be achieved in this group, hereby providing evidence that targeting PWID in treatment programmes is worthwhile. However, the extent to which such national efforts can reduce the HCV burden not only depends on the uptake into care and treatment success rates, it is also determined by the relative importance of within-country transmission and virus importation from elsewhere.
As the chronic nature of most HCV infections hampers reliably reconstructing contact networks from patient interviews, virus genetic data can be a valuable alternative source of information for elucidating the geographic history of virus lineages (e.g. [5], [6]). Using such data, we have recently shown that for the most prevalent subtype among PWID in Spain (40%, 7), HCV1a, infections often link to infections abroad – in recent years >50% link to Western European countries, mostly European Union (EU) member states – as opposed to other infections ...
Idioma: Inglés
DOI: 10.1016/j.jhep.2019.08.010
Año: 2019
Publicado en: JOURNAL OF HEPATOLOGY 71, 6 (2019), 1270-1272
ISSN: 0168-8278
Factor impacto JCR: 20.582 (2019)
Categ. JCR: GASTROENTEROLOGY & HEPATOLOGY rank: 2 / 88 = 0.023 (2019) - Q1 - T1
Factor impacto SCIMAGO: 6.817 - Hepatology (Q1)
Financiación: info:eu-repo/grantAgreement/ES/FEDER/RD16-0025-0040
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/PI15-00713
Tipo y forma: (PostPrint)
Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)
Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace. No puede utilizar el material para una finalidad comercial. Si remezcla, transforma o crea a partir del material, no puede difundir el material modificado.Exportado de SIDERAL (2021-02-24-12:54:45)
Enlace permanente:
Visitas y descargas
Este artículo se encuentra en las siguientes colecciones:
Artículos > Artículos por área > Medicina
Registro creado el 2021-02-24, última modificación el 2021-02-24